Genprex, Inc. (NASDAQ: GNPX) is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (“NSCLC”). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. For more information, visit the company’s website at www.Genprex.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
For more information please visit https://www.BioMedWire.
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
Breakthrough research conducted by a team at the University of Southern California (USC) has found…
New research conducted by UC San Diego researchers has revealed that adolescents and children having…
Financial momentum for Nutriband is indicated by its recent Q1 financial report Progress continues development…
The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…
The company offers a simple, AI-powered platform that helps providers identify their most valuable services,…
As the world watches Foxconn and NVIDIA deploy smart robotics in Taiwan’s cutting-edge hospitals, the…